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AbstrAct
Objectives To investigate patterns of early repeat 
prescriptions and treatment switching over an 11-year 
period to estimate differences in the cost of medication 
wastage, dispensing fees and prescriber time for short 
(<60 days) and long (≥60 days) prescription lengths 
from the perspective of the National Health Service in 
the UK.
setting Retrospective, multiple cohort study of primary 
care prescriptions from the Clinical Practice Research 
Datalink.
Participants Five random samples of 50 000 patients 
each prescribed oral drugs for (1) glucose control in type 
2 diabetes mellitus (T2DM); (2) hypertension in T2DM; 
(3) statins (lipid management) in T2DM; (4) secondary 
prevention of myocardial infarction; and (5) depression.
Primary and secondary outcome measures The volume 
of medication wastage from early repeat prescriptions and 
three other types of treatment switches was quantified 
and costed. Dispensing fees and prescriber time were 
also determined. Total unnecessary costs (TUC; cost of 
medication wastage, dispensing fees and prescriber 
time) associated with <60 day and ≥60 day prescriptions, 
standardised to a 120-day period, were then compared.
results Longer prescription lengths were associated 
with more medication waste per prescription. However, 
when including dispensing fees and prescriber time, 
longer prescription lengths resulted in lower TUC. This 
finding was consistent across all five cohorts. Savings 
ranged from £8.38 to £12.06 per prescription per 120 
days if a single long prescription was issued instead 
of multiple short prescriptions. Prescriber time costs 
accounted for the largest component of TUC.
conclusions Shorter prescription lengths could 
potentially reduce medication wastage, but they may 
also increase dispensing fees and/or the time burden of 
issuing prescriptions.
IntrOductIOn
Healthcare systems worldwide are increas-
ingly faced with the challenge of constraining 
rising pharmaceutical expenditures.1 One 
approach to addressing this problem is to 
ensure prescribed medication is used as 
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Research
strengths and limitations of this study
 ► Our analysis builds on existing methodological 
approaches to estimate the unnecessary costs 
associated with different prescription lengths, 
providing the only evidence available from the 
perspective of the National Health Service in the UK.
 ► Limitations of our study do risk biasing the results and 
the reported savings (£8.38–£12.06 per prescription 
per 120 days) should therefore be interpreted with 
caution and considered upper limits.
 ► Clinical Practice Research Datalink  (CPRD) 
prescription data only indicate whether a 
prescription has been issued and not whether it was 
dispensed or taken as recommended, potentially 
resulting in an overestimate or underestimate of the 
amount of wastage, depending on patient behaviour 
not captured in CPRD.
 ► The five case study conditions used in our study 
were purposively rather than randomly selected to 
represent the impact of repeat prescriptions and 
switching behaviour on wastage; they may not be 
representative of prescribing behaviour in other 
chronic conditions.
 ► Overlap of dates between prescriptions does not 
necessarily mean wastage has occurred and despite 
incorporating methods to account for this there is 
the possibility that our analysis approach could be 
overestimating the amount of medication wastage.
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Table 1 Case study conditions and associated prescriptions
Case study Relevant prescriptions/patient inclusion criteria
Glucose control with oral drug 
therapy in type 2 diabetes 
mellitus
Patients receiving one or more prescriptions for an oral antidiabetic drug listed under the BNF 
Section 6.1.2 Antidiabetic Drugs in any year from 2004 to 2014
Treatment of hypertension in 
type 2 diabetes mellitus
In addition to receiving an oral antidiabetic drug as defined in (1), patients receiving one or 
more prescriptions for any ACE inhibitors, angiotensin II receptor antagonists, calcium-channel 
blockers, beta-adrenoceptor blockers, alpha-adrenoceptor blockers, potassium-sparing 
diuretics and/or thiazide-like diuretics in any year from 2004 to 2014
Treatment with statins (lipid 
management) in type 2 
diabetes mellitus
In addition to receiving an oral antidiabetic drug as defined in (1), patients receiving one or 
more prescriptions for a statin in any year from 2004 to 2014
Treatment for the secondary 
prevention of myocardial 
infraction
In addition to receiving concurrent* prescriptions for an ACE inhibitor, antiplatelet and statin for 
at least 1 year in duration, patients receiving one or more prescriptions for beta-adrenoceptor 
blockers and/or angiotensin II receptor antagonists in any year from 2004 to 2014
Treatment of depression Patients receiving one or more prescriptions for any antidepressant drug listed under BNF 
Section 4.3 Antidepressant Drugs in any year from 2004 to 2014
(1) refers to the first row in the table, that is the relevant prescriptions/patient inclusion criteria for the case study "Glucose control with oral 
drug therapy in type 2 diabetes mellitus". 
*All patients receiving at least one prescription for an ACE inhibitor, antiplatelet drug and statin were first identified in Clinical Practice 
Research Datalink (CPRD). Patients from this sample that did not have at least four prescriptions (chosen to represent 1 year of therapy) 
for each of these drugs in at least one of the 11 years of data available (ie, 2004–2014) were excluded. From the remaining patients, the 
additional constraint of receiving one or more prescriptions for any beta-adrenoceptor blockers and/or angiotensin II receptor antagonists 
was applied to define the full sample.
BNF, British National Formulary.
efficiently as possible, minimising wastage. Wastage may 
occur when patients collect repeat prescriptions early, or 
when changes are made to patients’ drug regimens. Intu-
itively, the more drugs a patient has in her/his possession 
at the time of a repeat prescription or regimen change, 
the higher the wastage. Therefore, limiting the quan-
tity of medication through shorter prescription lengths 
could minimise wastage and help contain expenditure. 
However, the resulting higher frequency of prescriptions 
will have the unintended consequence of increasing 
transactions costs, specifically dispensing fees charged by 
pharmacists and healthcare professionals’ time to issue 
them.
Several studies have examined the costs associated 
with issuing either long (3 months) or short (1 month) 
supplies of prescriptions.2–7 In general, these concluded 
that shorter prescriptions were associated with lower 
wastage and hence reduced cost, but the increased trans-
action costs of shorter prescriptions more than offset 
these savings. These studies are all US based, which have 
very different healthcare systems from the UK, partic-
ularly with regard to the cost and dispensing of drugs. 
Therefore, the generalisability of these conclusions to 
the UK is questionable. Furthermore, none of the studies 
include healthcare professionals’ time burden associated 
with issuing prescriptions.
In this study, we estimate differences in the costs of 
medication wastage and transaction costs (in terms of 
dispensing fees and prescriber time) in patients receiving 
medications within the National Health Service (NHS) in 
the UK as either short or long prescription lengths for 
five drugs/classes of drugs prescribed in primary care for 
common, chronic conditions.
MethOds
Overview
We undertook an analysis of Clinical Practice Research 
Datalink (CPRD)8 prescription data to estimate the 
cost of medication wastage associated with shorter and 
longer prescription lengths for drugs used to treat five 
case study conditions. In order to estimate the net cost 
impact of shorter and longer prescription lengths, the 
costs of dispensing fees and prescriber time to issue a 
prescription were also assessed.
study design and inclusion criteria
This retrospective multicohort study evaluated medica-
tion wastage and its associated cost plus dispensing fees 
and the cost associated with issuing a prescription (ie, 
a general practitioner (GP) completing the process of 
producing a prescription; note this does not include clin-
ical decision-making time or administrative staff time) in 
five condition-specific, random samples of 50 000 patients 
each, obtained from CPRD.
We derived the five samples from all adult patients 
(≥18 years old) receiving one or more prescriptions for 
at least one medication relevant to a case study of interest 
(table 1) between 1 January 2004 and 31 December 2014. 
In line with other studies of CPRD, data9 10 inclusion was 
restricted to patients with complete data for two variables 
(numeric daily dose (ndd) and quantity (qty)) required 
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to calculate the prescription duration. The five case 
studies were defined using unique lists of product codes 
(CPRD unique code for treatment selected by the GP). 
They were: (1) glucose control with oral drug therapy 
in type 2 diabetes mellitus (T2DM); (2) treatment of 
hypertension in T2DM; (3) treatment with statins (lipid 
management) in T2DM; (4) treatment for the secondary 
prevention of myocardial infarction (MI); and (5) treat-
ment of depression.
These were selected for study based on the chronic 
nature and prevalence of the associated condition within 
the population, the potential for a variety of prescription 
changes over the course of treatment and the fact that 
medications used in their treatment have stable dosing 
once therapeutic effect has been achieved, making either 
short or long prescription clinically appropriate.7 Defini-
tions of the relevant prescriptions and product code lists 
of the potentially prescribed medications for each of the 
five case studies are provided in table 1 and online supple-
mentary appendix I, respectively. Sample data counts are 
provided in online supplementary appendix II.
treatment patterns evaluated
For each cohort, data for each patient were first ordered 
in sequence from earliest to latest prescription date. To 
identify treatment patterns, three main variables were 
used: (1) product code (used to identify a unique dosage, 
formulation and brand (or generic version) of one partic-
ular drug); (2) drug substance (used to identify different 
dosages and/or formulations of the same drug chemical 
substance); and (3) drug class (used to identify drugs with 
different, but related chemical composition, with similar 
mechanisms of action based on their categorisation in the 
British National Formulary). Four different prescription 
patterns in an individual’s sequence of prescriptions were 
identified: (1) repeat prescriptions of the same product 
code; (2) substitutions between different dosages or 
formulations of the same drug substance; (3) substitu-
tions between drugs that are in the same class; and (4) 
substitutions between drugs that have similar clinical 
indications from different classes. Prescriptions issued on 
the same day for drugs in the same class with different 
product codes were considered prescriber error and the 
duplicates were dropped from the analysis. The exception 
to this was for antiplatelet drugs in secondary prevention 
of MI, as it was assumed that two different antiplatelet 
drugs could be prescribed at the same time. In addition, 
prescriptions for medications with similar clinical indi-
cations from different classes issued on the same day 
were not counted as a switch, but rather as an add-on to 
existing therapy or concomitant therapy (online supple-
mentary appendix II).
Analysis of wastage
Wastage from early repeat prescriptions (pattern 1) 
was based on a cumulative excess supply built up over a 
period of 1 year. This avoided overestimation of wastage 
where a patient filled a prescription a few days early, but 
then finished their previous supply before starting the 
new one. In estimating wastage from switches (patterns 
2–4), we adapted a previous approach6 to differen-
tiate between add-ons/concomitant therapy and actual 
switches. If the difference between the number of 
changes between medications with similar clinical indi-
cations from different classes and the number of unique 
drug classes within a rolling annual period was ≥1, then 
any overlap in prescription dates was considered to be an 
add-on rather than a switch. This is illustrated in table 2. 
Similar constraints were also applied in three of the case 
studies (ie, the glucose control in T2DM, treatment of 
hypertension in T2DM and secondary prevention of 
myocardial infraction cohorts) due to the potential for 
a number of the included therapies to be given concomi-
tantly (online supplementary appendix III).
costs
To estimate the costs of wastage, defined daily doses 
(DDD) associated with each drug substance code in the 
five cohorts were first obtained from the WHO’s ATC/
DDD Index 2016.11 The Prescription Cost Analysis 2015, 
which provides details of the quantity of individual doses 
and net ingredient costs (NIC) of all the prescriptions in 
England,12 was used to determine an NIC/quantity value 
of a specific strength of the medication associated with 
each drug substance code. This value was standardised 
using the associated DDD to obtain a cost per day for each 
drug substance code in all five of the cohorts. Details of 
these calculations are provided in online supplementary 
appendix IV.
Dispensing fees from the Drug Tariff (£0.90 per standard 
prescription and 2% of the cost per prescription (cost per 
day multiplied by prescription length) for prescriptions 
over £100)13 and the estimated cost of physician or nurse 
time to issue a prescription were determined for each 
prescription. Time to issue a prescription was extracted 
from a targeted literature review (online supplementary 
appendix V). It should be noted that none of the iden-
tified studies reported times from a UK-specific primary 
care context. It was therefore necessary to prioritise the 
use of available evidence based on studies with the largest 
sample sizes and those studies reporting prescriber time 
for different types of prescriptions. Repeat prescriptions 
were assigned a shorter time compared with changes in 
dose/formulation, within drug classes and between drug 
classes (48.7 vs 61.2 s).14 Per minute costs related to GPs’ 
time (£3.80/min) or a general practice nurse’s time 
(£0.93/min) were then applied.15 All costs are reported 
in 2015 GBP.
statistical analysis
Descriptive analyses of trends in treatment switching 
and early repeat prescriptions were used to assess medi-
cation wastage. The proportion of days’ supply wasted, 
mean number of days’ supply wasted and the mean 
costs of wastage per prescription were determined for 
two prescription lengths (<60 and ≥60 days, hereafter 
 o
n
 5 June 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019382 on 4 December 2017. Downloaded from 
4 Doble B, et al. BMJ Open 2017;7:e019382. doi:10.1136/bmjopen-2017-019382
Open Access 
box example comparing total unnecessary costs 
for <60 day and ≥60 day prescription lengths for a 
standardised time period of 120 days
Assume on average that the <60 day prescription length is 35 days 
and the average ≥60 day prescription length is 120 days. Also assume 
that regardless of prescription length, patients on average switch 
their prescription 30 days after a prescription is issued. The quantity 
used is therefore 30 days for both prescription lengths (Q
days used<60 
= Qdays used≥60 = 30), but the quantity wasted is much larger for 
the ≥60 day prescription (90 days compared with only 5 days wasted). 
Since over a 120-day period both prescription lengths will incur the 
same dispensing fees and prescriber time costs (four prescriptions 
will be issued regardless of prescription length as a switch occurs 
every 30 days), the ≥60 day prescription will be associated with higher 
total unnecessary costs. Note that this example has been developed 
by adapting an example provided by Walton et al5 to the prescription 
lengths considered in our study.
Table 2 Example of differentiating between treatment switches and add-ons for a patient receiving medications for 
hypertension
Year
Sequence of 
prescriptions 
in year Drug Class
Total number of 
treatment switches 
between classes in 
year (A)
Total number of 
unique classes 
in year (B)
Difference 
for year
(A)−(B)
Count as 
treatment 
switch 
between 
classes*
Count as 
add-on
2011 1 Ramipril ACE 1 2 −1 No No
2011 2 Losartan potassium ARA Yes No
2011 3 Losartan potassium ARA No No
2011 4 Losartan potassium ARA No No
2012 1 Losartan potassium ARA 2 2 0 No No
2012 2 Diltiazem hydrochloride CCB No Yes
2012 3 Diltiazem hydrochloride CCB No No
2012 4 Losartan potassium ARA No Yes
2013 1 Losartan potassium ARA 4 2 2 No No
2013 2 Doxazosin AAB No Yes
2013 3 Losartan potassium ARA No Yes
2013 4 Doxazosin AAB No Yes
2013 5 Losartan potassium ARA No Yes
*For the treatment of hypertension in type 2 diabetes mellitus (T2DM) cohort, overlaps in prescription dates involving ACE inhibitors and 
angiotensin II receptor antagonists with either calcium-channel blockers or thiazide-like diuretics were not counted as switches as these 
therapies are commonly administered together as second-line therapy.20
AAB, alpha-adrenoceptor blocker; ARA, angiotensin II receptor antagonist; CCB, calcium-channel blocker.
In 2011, the patient has one change between clinically related drugs from different classes (ramipril to losartan) and receives medication 
belonging to two unique drug classes (ACE and ARA). One minus two is <1, so this change is considered a switch. The rationale being that 
if the number of changes was small or large and the number of unique drugs involved in the changes was also small or large, respectively, 
switches in therapies were occurring and therefore there was potential for wastage to occur. In 2012, the patient has two changes between 
clinically related drugs from different classes (losartan to diltiazem and diltiazem to losartan) and receives medication belonging to two unique 
drug classes (ARA and CCB). Two minus two is <1, which indicates a switch, but in the treatment of hypertension, ARAs and CCBs are 
commonly administered together as second-line therapy20 and therefore these two changes were considered add-ons/concomitant therapy. 
In 2013, the patient has four changes between clinically related drugs from different classes (losartan to doxazosin, doxazosin to losartan, 
losartan to doxazosin, and doxazosin to losartan) and receives medication belonging to two unique drug classes (ARA and AAB). Four minus 
two is ≥1, which indicates the four changes are add-ons, not switches. The rationale being that if the number of changes was large, but the 
number of unique drugs involved in the changes was low, an add-on or concomitant therapy was being prescribed and no wastage was 
occurring.
‘short’ and ‘long’ prescriptions) over the 11-year period. 
Mean cost of wastage per prescription was reported for 
each of the four treatment patterns individually and 
for all treatment patterns combined for each annual 
period. Two-sample t-tests using groups (<60 and ≥60 
day prescription lengths) assuming unequal variance 
were used to compare the differences between the <60 
day and ≥60 day groups.
To determine and compare the total unnecessary costs 
(TUC; cost of medication wastage, dispensing fees and 
prescriber time) associated with short and long prescrip-
tion lengths, a model originally used by Walton et al5 was 
adapted and applied to the prescription data from the 
five cohorts (online supplementary appendix VI), and 
the two equations below were used, where ‘C’ represents 
cost and ‘Q’ represents quantity. An example of calcula-
tion is provided in box.
 
TUC<60 = (Cwastage<60 + Cdispensing<60 + Cprescribertime<60)
×(120/Qdaysused<60)− (Cdispensing<60 + Cprescribertime<60) (1)
 
TUC60 = (Cwastage60 + Cdispensing60 + Cprescribertime60)
×(120/Qdaysused60)− (Cdispensing60 + Cprescribertime60) (2)
One-way sensitivity analyses were conducted to 
examine differences in TUC under a variety of different 
scenarios, including scenarios assuming nurses issued 
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the prescription instead of a GP, excluding prescriber 
time costs, accounting for changes in NHS revenue 
from patient charges per prescription, ±50% mean days 
wasted, ±50% the mean cost of drugs per day, dispensing 
fees and prescriber time.
All statistical analyses were performed using Stata/MP 
V.13.1 (StataCorp, College Station, Texas, USA).
results
Overall cohort selection
The proportion of observations dropped from the full 
sample due to missing or observations equal to zero in 
either the ndd or qty variables ranged from 6% in both 
the lipid management and hypertension cohorts to 21% 
in the glucose control in T2DM cohort. The numbers of 
observations were further reduced after accounting for 
prescription error (online supplementary appendix II).
Medication wastage
Over the 11-year study period, there was a statistically 
significant difference in the proportion of days’ supply 
wasted, mean number of days’ supplied wasted and the 
mean cost of wastage per prescription between the short 
and long prescription groups for all five of the case studies 
(online supplementary appendix VIII). The proportion 
of days’ supply wasted was consistently larger for the long 
prescription group across all cohorts except depression 
where the short group had 6.3% of days’ supply wasted 
compared with 3.7% in the longer group. The mean 
number of days’ supply wasted was also consistently 
larger for the longer group, but the difference between 
the two prescription length groups was much smaller for 
the depression cohort in comparison to the other four 
cohorts.
Medication wastage by treatment pattern
In four of the five cohorts, mean cost of wastage per 
prescription was significantly higher with longer prescrip-
tion lengths for all four treatment patterns (table 3). The 
one exception was for the depression cohort where the 
mean cost of wastage per prescription for both dosage/
formulation and within-class treatment switches did not 
show statistically significant differences between the two 
prescription length groups. The repeat prescription treat-
ment pattern consistently had the largest mean cost of 
wastage per prescription across the cohorts, particularly 
for the longer groups, except for the depression cohort. 
The lipid management cohort did not report any between-
class treatment switches as all medications included in the 
analysis were from the same class of statins.
Medication wastage over time
On an annual basis, mean cost of wastage per prescription 
was significantly higher in the longer prescription lengths 
for each study year, except 2012 and 2013 for depres-
sion (online supplementary appendix IX). In general, 
the magnitude of the mean costs remained relatively 
consistent over the study period, except for a few notable 
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Figure 1 Trends in the mean cost of medication wastage per prescription over 11-year study period.
trends (figure 1). In the glucose control in T2DM cohort, 
the mean costs for the longer group in years 2004 and 
2011 were slightly larger (range £1.81–£3.14) compared 
with the other nine annual means (range £0.87–£1.40). 
In the hypertension cohort, there was a slight trend 
of decreasing magnitude of the mean cost over the 11 
years for the shorter group; a decrease in mean cost was 
limited to years 2013 and 2014 in the longer group. For 
both the lipid management and secondary prevention of 
MI cohorts, the magnitude of the mean costs remained 
relatively consistent over the 11 years for the shorter 
prescription length groups, whereas there was a slightly 
decreasing trend in the magnitude of the mean costs for 
the longer prescription length groups.
differences in tucs for short and long prescription lengths
TUC (wastage, dispensing fees and prescriber time) per 
120 days was lower in the longer prescription group for all 
five cohorts (savings of £8.38 (glucose control in T2DM) 
to £12.06 (secondary prevention of MI) per prescrip-
tion per 120 days if a single long prescription was issued 
instead of multiple short prescriptions, online supple-
mentary appendix X). This roughly translates into savings 
of £25.14–£36.18 per patient per year assuming patients 
would receive three prescriptions each with a 120-day 
supply instead of 12 prescriptions each with a 30-day 
supply.
Sensitivity analysis shows longer prescriptions remained 
cost saving compared with shorter prescriptions across all 
scenarios and ranges tested. The magnitude of the savings 
was lowest when prescriber time costs were excluded from 
the models (range £0.91–£2.81 per prescription per 120 
days) and reduced to a lesser extent when nurse prescriber 
time costs were used instead of physician’s (range £5.94–
£8.48 per prescription per 120 days) and when loss 
of revenue to the NHS through a reduced number of 
prescription charges paid by patients was incorporated 
into the models (range £6.52–£9.83 per prescription 
per 120 days). The other scenarios tested had relatively 
little impact on the magnitude of the savings, with the 
exception of increases and decreases of 50% in the cost 
of prescriber time (online supplementary appendix X).
dIscussIOn
summary of findings
Longer prescription lengths are associated with more 
medication wastage per prescription compared with 
shorter prescription lengths. However, after taking into 
account transaction costs, longer prescription lengths are 
associated with overall cost savings (lower TUC) compared 
with shorter ones. In all five cohorts, most prescriptions 
were for ≤30 days with relatively small proportions of 
patients having prescription lengths between 31 and 60 
days (18%, 27%, 28%, 27% and 25% for the depression, 
T2DM, hypertension, lipid management and MI cohorts, 
respectively). Ninety-five per cent of prescriptions in the 
depression cohort were for <60 days. Some 39 million 
prescriptions are issued for antidepressants in the UK 
each year,16 therefore, if the 95% issued as <60 day supplies 
was instead issued as longer ≥60 day prescriptions the 
total savings to the NHS could be as much as £408 million 
per year. Similarly, knowing 97.05% of statin prescriptions 
were issued as <60 day prescriptions from our CPRD anal-
ysis, the total savings to the NHS just in England could 
be as much as £563 million per year if the ~61.1 million17 
short statin prescriptions issued in 2015 for two statins 
(simvastatin and atorvastatin) were changed to longer 
prescriptions. However, it is critical to note that the 
majority of savings for both examples will not be cash 
releasing, but will be realised as savings in GP time, which 
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could be used to increase primary care consultations with 
patients. Cash-releasing savings may come from reduced 
dispensing fees, for which we estimate an upper limit of 
£104 million and £62 million for antidepressants and the 
statins, respectively. However, these cash savings will come 
at the expense of community pharmacies that may rely 
on dispensing fees to support their businesses, a fact that 
should be considered if longer prescription lengths are 
to be adopted in practice. The magnitude of the savings 
for the other case studies will be of a similar scale given 
the prevalence of the conditions and frequency of shorter 
prescriptions. These figures should be interpreted with 
caution as they assume it is clinically appropriate for all 
prescriptions to be issued for a longer duration, which 
will certainly not be the case.
comparison to previous studies
Several other studies have examined the costs associated 
with issuing either long (3 months) or short (1 month) 
supplies of prescriptions.2–7 These studies all take the 
perspective of various payers in the USA (eg, different 
state-level Veterans Affairs and Medicaid programmes 
as well as a non-institutionalised civilian population) 
and account for different cost items. Two studies found 
savings associated with longer prescriptions of a similar 
magnitude to ours, for example, TUC of US$2.45 (£1.63 
at April 2015 exchange rates)5 and US$6.17 (£4.10).3 The 
former study5 excluded prescriber time (the equivalent 
figure in our study is £1.03), and the latter3 included costs 
of mail-order prescriptions.
Another study calculated per patient per year savings 
of US$7.70 (statins) to US$26.86 (oral hypoglycaemics) 
associated with 90-day vs 30-day prescriptions.6 A study 
of the financial impact on healthcare payers4 detected 
statistically significant savings with 3-month supplies in 
only two of six cases as most savings accrued to patients 
through reductions in out-of-pocket costs. This study 
did not consider the cost of medication wastage making 
comparison with our study difficult. A simulation study 
found that any savings from reduced wastage from a 
shorter prescription length were more than offset by 
increases in dispensing fees as long as the dispensing fee 
was at least US$2.40 (base case assumption was US$5.60).2
In contrast to these, a comprehensive study on the 
impact of a policy to reduce the maximum prescription 
length from 100 to 34 days’ supply in the North Caro-
lina Medicaid programme7 found that total Medicaid 
expenditures (comprising outpatient, inpatient, emer-
gency as well as pharmacy costs) decreased for patients 
initially receiving 100-day prescriptions after the imple-
mentation of the 34-day policy (range US$245–US$440 
per person per quarter across six classes of medications 
(antihypertensives, antidiabetic medications, lipid-low-
ering drugs, seizure-disorder medications, antidepres-
sants and antipsychotics) assessed). However, the results 
are not broken down by expenditure category (except 
for reporting decreases in expenditures for the targeted 
prescriptions across all six medication classes) and 
therefore it is unclear where the savings are accrued. This 
finding may be explained by small adverse health effects 
as a result of changes in adherence, patients absorbing 
any health effects through informal care or tolerating 
greater disease burden, or the follow-up period of the 
study (18 months after implementation) being too short 
to capture any spillover effects of decreased adherence 
on other Medicaid services. The equivalent impact on 
NHS expenditure in the UK may differ due to differ-
ences in the organisation of care, in particular the gate-
keeper role of primary care. Analysis of this was outside 
the scope of our analysis but would be a valuable future 
line of enquiry.
study lIMItAtIOns
To the best of the authors’ knowledge, this study provides 
the only evidence of the unnecessary costs associated 
with different prescription lengths from the perspective 
of the NHS in the UK and builds on existing method-
ological approaches available in the literature. However, 
there are a few limitations that warrant discussion. First, 
CPRD prescription data only indicate whether a prescrip-
tion has been issued and not whether it was dispensed 
or taken as recommended. Our estimates may, therefore, 
either overstate or understate the amount of wastage that 
actually occurred, depending on patient behaviour not 
captured in CPRD.
Second, the five case study conditions were purposively 
rather than randomly selected to represent the impact of 
repeat prescriptions and switching behaviour on wastage; 
they may not be representative of prescribing behaviour 
in other chronic conditions. However, those selected do 
represent some of the most common chronic conditions 
treated with prescribed medications. Nine of the top 
20 prescribed medications within NHS England were 
included in at least one of the case study conditions in 
our analyses, and combined they accounted for around 
£378 million (4%) of all drug expenditures within NHS 
England in 2015 and are therefore highly policy rele-
vant.17 Our analysis also excluded patients having one or 
more observations with missing or zero values for either 
the ndd and/or qty variables. If this was non-random then 
the subsequent samples may not be truly representative of 
the general population. Appropriate methods to impute 
these variables are of limited value and our approach was 
similar to other studies using CPRD data.9 10
Third, the identification of patients within CPRD for 
the five case studies (table 1) was based solely on product 
codes, rather than in conjunction with medical diag-
noses. It is therefore possible that some of the patients in 
the five cohorts may be receiving medications for other 
conditions not of specific interest in our study (eg, anti-
depressants used for anxiety or metformin used for poly-
cystic ovary disease). However, as the main aim of our 
study was to estimate drug wastage, the possible inclusion 
of patients with conditions outside our cohort defini-
tions still provided our analysis with relevant information 
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concerning drug wastage, dispensing fees and prescriber 
time.
Fourth, an overlap of dates between prescriptions does 
not necessarily mean wastage has occurred as consumption 
of early repeat prescriptions may be delayed until the initial 
supply is exhausted and treatment changes might actu-
ally be add-ons to existing prescriptions or concomitant 
therapy rather than switches in therapy. To ensure wastage 
was not overestimated, a threshold of 1 year after the initial 
prescription in a particular series was used to estimate 
wastage for early repeat prescriptions, and a threshold 
of <1 in the difference between the number of drug 
changes between medications with similar clinical indi-
cations from different classes and the number of unique 
drug classes within an annual period was used to identify 
wastage from between-class treatment switches. There is, 
however, the possibility that our analysis approach could be 
overestimating the amount of medication wastage.
Fifth, for pragmatic purposes we dichotomised prescrip-
tion lengths into ‘short’ versus ‘long’, with a cut-off of 
60 days. This will have classified 56-day prescriptions as 
‘short’. While this will have resulted in a loss of sensitivity 
(there may be differences in TUC between 1 and 2-month 
prescriptions), the overall conclusions comparing 
‘shorter’ (<60 days) and ‘longer’ (≥60 days) lengths are 
not affected.
Finally, a number of assumptions were required to 
assign unit costs to the estimated proportions of wastage. 
Mean cost per day values derived using DDDs, NICs and 
quantities at the drug substance level were calculated and 
then applied to any prescription categorised under that 
particular drug substance. This approach is not ideal, but 
necessary given the inability to link CPRD data to indi-
vidual unit costs specific for each prescription. The direc-
tion and magnitude of any resulting bias are difficult to 
predict.
Furthermore, NICs do not include any discounts that 
may be applied or include any adjustment for revenue 
received by the NHS where a prescription charge is 
paid at the time the prescription is dispensed or where 
the patient has purchased a prepayment certificate, and 
therefore may be different from the net cost incurred 
specifically by the NHS. Patients with T2DM are exempt 
from the prescription charge,18 and overall almost 90% 
of prescriptions dispensed in the NHS in England are 
exempt.19
All these limitations risk biasing the results. The 
projected savings should therefore be interpreted with 
caution and in any case be considered upper limits. Our 
analysis focused on drugs with low unit costs prescribed to 
large numbers of patients. The results may not be gener-
alisable to high-cost drugs used to treat relatively small 
patient groups.
cOnclusIOns
Overall, the findings from the study indicate that from 
the perspective of the NHS in the UK, longer prescription 
lengths are cost-saving relative to shorter prescription 
lengths in a number of common chronic diseases. Poli-
cymakers should recommend that GPs consider issuing 
longer prescriptions for common chronic conditions 
where clinically appropriate to minimise the costs associ-
ated with dispensing fees and prescriber time as a result 
of issuing multiple prescriptions of shorter length.
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